| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eddba5db49659b527d67801ac07801c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81c02e88b56b9e05dee1fa109004258f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d1f82b83281de58fcf287d0fcdc45f2c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
2018-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11b98d76e255d565596c989694439b6d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e3baaf16ab72a272d2cdfc6324f116c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5e38d25e95edc84603c87e278227672
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc40a2a753839836da70c305f27d10c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07a73f5476c2f251541dda244bcf822e |
| publicationDate |
2019-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2018234068-A1 |
| titleOfInvention |
Antigen receptors and uses thereof |
| abstract |
The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors. |
| priorityDate |
2017-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |